ZOM — Zomedica Income Statement
0.000.00%
Last trade - 00:00
- $135.23m
- $30.78m
- $18.93m
- 31
- 40
- 29
- 25
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 4.13 | 18.9 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 3.05 | 13.7 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 16.6 | 19.8 | 16.8 | 25 | 40.9 |
Operating Profit | -16.6 | -19.8 | -16.8 | -20.8 | -21.9 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16.6 | -19.8 | -16.9 | -20.7 | -19.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.6 | -19.8 | -16.9 | -18.4 | -17 |
Net Income Before Extraordinary Items | |||||
Net Income | -16.6 | -19.8 | -16.9 | -18.4 | -17 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.6 | -19.8 | -16.9 | -18.4 | -17 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.177 | -0.186 | -0.046 | -0.019 | -0.017 |